Oxford Biodynamics PLC (OBD) - Total Liabilities

Latest as of March 2026: GBX5.84 Million GBX ≈ $710.32 USD

Based on the latest financial reports, Oxford Biodynamics PLC (OBD) has total liabilities worth GBX5.84 Million GBX (≈ $710.32 USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Oxford Biodynamics PLC (OBD) investment intensity to see how much of total assets are deployed in long-term investments.

Oxford Biodynamics PLC - Total Liabilities Trend (2013–2025)

This chart illustrates how Oxford Biodynamics PLC's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Oxford Biodynamics PLC asset portfolio.

Oxford Biodynamics PLC Competitors by Total Liabilities

The table below lists competitors of Oxford Biodynamics PLC ranked by their total liabilities.

Company Country Total Liabilities
Heavitree Brewery
LSE:HVT
UK GBX5.16 Million
Nanoco Group plc
LSE:NANO
UK GBX37.64 Million
Image Scan Holdings Plc
LSE:IGE
UK GBX487.00K
Mercantile Ports & Logistics Ltd
LSE:MPL
UK GBX53.22 Million
Proteome Sciences PLC
LSE:PRM
UK GBX17.79 Million
Tiger Royalties and investments Plc
LSE:TIR
UK GBX91.36K
Serinus Energy
LSE:SENX
UK GBX50.04 Million
Seed Innovations Ltd
LSE:SEED
UK GBX153.00K

Liability Composition Analysis (2013–2025)

This chart breaks down Oxford Biodynamics PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Oxford Biodynamics PLC (OBD) net asset quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.01 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.80 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.64 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Oxford Biodynamics PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Oxford Biodynamics PLC (2013–2025)

The table below shows the annual total liabilities of Oxford Biodynamics PLC from 2013 to 2025.

Year Total Liabilities Change
2025-09-30 GBX6.97 Million
≈ $848.05
-10.06%
2024-09-30 GBX7.75 Million
≈ $942.95
-23.05%
2023-09-30 GBX10.07 Million
≈ $1.23K
+15.03%
2022-09-30 GBX8.76 Million
≈ $1.07K
+0.81%
2021-09-30 GBX8.69 Million
≈ $1.06K
+390.18%
2020-09-30 GBX1.77 Million
≈ $215.60
+47.91%
2019-09-30 GBX1.20 Million
≈ $145.76
+34.30%
2018-09-30 GBX892.00K
≈ $108.53
-17.71%
2017-09-30 GBX1.08 Million
≈ $131.89
-15.11%
2016-09-30 GBX1.28 Million
≈ $155.37
+82.95%
2015-09-30 GBX698.00K
≈ $84.93
-26.37%
2014-09-30 GBX948.00K
≈ $115.34
+43.64%
2013-09-30 GBX660.00K
≈ $80.30
--

About Oxford Biodynamics PLC

LSE:OBD UK Diagnostics & Research
Market Cap
$60.04K
GBX493.45 Million GBX
Market Cap Rank
#31604 Global
#1186 in UK
Share Price
GBX0.12
Change (1 day)
+0.00%
52-Week Range
GBX0.09 - GBX0.59
All Time High
GBX274.50
About

Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that y developing, and commercializing precision medicine tests for life-changing diseases in the United States and the United Kingdom. The company provides EpiSwitch CiRT (Checkpoint inhibitor Response Test), a blood test that predicts an individual patient's therapeutic response to checkpoint inhibitor i… Read more